Table 1.
Molecular mass determination by AUC and MALS
| Protein | Molecular mass (kDa) by AUC | Molecular mass (kDa) by MALS |
| gp140–FL20* | 411 ± 8 | 422 ± 1 |
| gp140–FL20 + CD4† | 438 ± 6 (2D CD4) | 464 ± 3 (4D CD4) |
| gp140–FL20 + VRC01 Fab | 532 ± 9 | 548 ± 3 |
| gp140–FL20 + CD4 + 412d (or 17b) Fab‡ | 480 ± 11 (2D CD4) | 504 ± 5 (4D CD4) |
| gp120-fd | 380 ± 15 | 375 ± 9 |
| gp120-fd + CD4 | 443 ± 8 (2D CD4) | 511 ± 6 (4D CD4) |
| gp120-fd + VRC01 Fab | 520 ± 12 | 520 ± 10 |
| gp120-fd + CD4 + 17b Fab | n.d.g | 644 ± 5 (4D CD4) |
| 4D CD4 | n.d. | 46 ± 8 |
| VRC01 Fab | n.d. | 52 ± 4 |
| 17b Fab | n.d. | 51 ± 6 |
AUC, analytical ultracentrifugation; MALS, multiangle light scattering; n.d., not determined. Detailed data analyses are shown in Figs. S1 and S2.
*
All envelope constructs are derived from the HIV-1 92UG037.8 sequence.
†
CD4, 2 domain soluble CD4 was used for AUC and 4 domain CD4 used for MALS.
‡
412d was used for AUC and 17b was used for MALS.